Stalfort John A Iii - Net Worth and Insider Trading
Stalfort John A Iii Net Worth
The estimated net worth of Stalfort John A Iii is at least $25 Million dollars as of 2024-11-29. Stalfort John A Iii is the Director of Dova Pharmaceuticals Inc and owns about 635,665 shares of Dova Pharmaceuticals Inc (DOVA) stock worth over $18 Million. Stalfort John A Iii is the Director of Taysha Gene Therapies Inc and owns about 1,933,671 shares of Taysha Gene Therapies Inc (TSHA) stock worth over $6 Million. Stalfort John A Iii is also the Director of Acumen Pharmaceuticals Inc and owns about 303,919 shares of Acumen Pharmaceuticals Inc (ABOS) stock worth over $686,857. Besides these, Stalfort John A Iii also holds Verrica Pharmaceuticals Inc (VRCA) . Details can be seen in Stalfort John A Iii's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Stalfort John A Iii has not made any transactions after 2023-08-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Stalfort John A Iii
Stalfort John A Iii Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Stalfort John A Iii owns 4 companies in total, including Verrica Pharmaceuticals Inc (VRCA) , Dova Pharmaceuticals Inc (DOVA) , and Acumen Pharmaceuticals Inc (ABOS) among others .
Click here to see the complete history of Stalfort John A Iii’s form 4 insider trades.
Insider Ownership Summary of Stalfort John A Iii
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc | 2020-08-14 | director |
| DOVA | Dova Pharmaceuticals Inc | 2019-11-12 | director |
| ABOS | Acumen Pharmaceuticals Inc | 2021-07-06 | director |
 | | 2023-08-16 | director |
Stalfort John A Iii Latest Holdings Summary
Stalfort John A Iii currently owns a total of 4 stocks. Among these stocks, Stalfort John A Iii owns 635,665 shares of Dova Pharmaceuticals Inc (DOVA) as of December 20, 2018, with a value of $18 Million and a weighting of 71.63%. Stalfort John A Iii owns 1,933,671 shares of Taysha Gene Therapies Inc (TSHA) as of August 16, 2023, with a value of $6 Million and a weighting of 23.31%. Stalfort John A Iii also owns 303,919 shares of Acumen Pharmaceuticals Inc (ABOS) as of July 6, 2021, with a value of $686,857 and a weighting of 2.76%. The other 1 stocks Verrica Pharmaceuticals Inc (VRCA) have a combined weighting of 2.3% among all his current holdings.
Latest Holdings of Stalfort John A Iii
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DOVA | Dova Pharmaceuticals Inc | 2018-12-20 | 635,665 | 28.04 | 17,824,047 |
| TSHA | Taysha Gene Therapies Inc | 2023-08-16 | 1,933,671 | 3.00 | 5,801,013 |
| ABOS | Acumen Pharmaceuticals Inc | 2021-07-06 | 303,919 | 2.26 | 686,857 |
| VRCA | Verrica Pharmaceuticals Inc | 2020-08-14 | 462,110 | 1.24 | 573,016 |
Holding Weightings of Stalfort John A Iii
Stalfort John A Iii Form 4 Trading Tracker
According to the SEC Form 4 filings, Stalfort John A Iii has made a total of 0 transactions in Dova Pharmaceuticals Inc (DOVA) over the past 5 years. The most-recent trade in Dova Pharmaceuticals Inc is the acquisition of 31,000 shares on December 20, 2018, which cost Stalfort John A Iii around $194,060.
According to the SEC Form 4 filings, Stalfort John A Iii has made a total of 1 transactions in Taysha Gene Therapies Inc (TSHA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Taysha Gene Therapies Inc is the acquisition of 777,778 shares on August 16, 2023, which cost Stalfort John A Iii around $700,000.
According to the SEC Form 4 filings, Stalfort John A Iii has made a total of 1 transactions in Acumen Pharmaceuticals Inc (ABOS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Acumen Pharmaceuticals Inc is the acquisition of 35,000 shares on July 6, 2021, which cost Stalfort John A Iii around $560,000.
More details on Stalfort John A Iii's insider transactions can be found in the Insider Trading History of Stalfort John A Iii table.Insider Trading History of Stalfort John A Iii
- 1
Stalfort John A Iii Trading Performance
GuruFocus tracks the stock performance after each of Stalfort John A Iii's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stalfort John A Iii is 8.88%. GuruFocus also compares Stalfort John A Iii's trading performance to market benchmark return within the same time period. The performance of stocks bought by Stalfort John A Iii within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Stalfort John A Iii's insider trading performs compared to the benchmark.
Performance of Stalfort John A Iii
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 28.06 | | | | | |
| Relative Return to S&P 500(%) | 24.48 | | | | | |
Stalfort John A Iii Ownership Network
Stalfort John A Iii Owned Company Details
What does Verrica Pharmaceuticals Inc do?
Who are the key executives at Verrica Pharmaceuticals Inc?
Stalfort John A Iii is the director of Verrica Pharmaceuticals Inc. Other key executives at Verrica Pharmaceuticals Inc include director & President and CEO Ted White , Chief Commercial Officer Joe Bonaccorso , and General Counsel Christopher G. Hayes .
Verrica Pharmaceuticals Inc (VRCA) Insider Trades Summary
Over the past 18 months, Stalfort John A Iii made no insider transaction in Verrica Pharmaceuticals Inc (VRCA). Other recent insider transactions involving Verrica Pharmaceuticals Inc (VRCA) include a net sale of 150,999 shares made by Ted White , a net sale of 130,386 shares made by Joe Bonaccorso , and a net sale of 124,941 shares made by Christopher G. Hayes .
In summary, during the past 3 months, insiders sold 0 shares of Verrica Pharmaceuticals Inc (VRCA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 533,677 shares of Verrica Pharmaceuticals Inc (VRCA) were sold and 2,260,199 shares were bought by its insiders, resulting in a net purchase of 1,726,522 shares.
Verrica Pharmaceuticals Inc (VRCA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Verrica Pharmaceuticals Inc Insider Transactions
Stalfort John A Iii Mailing Address
Above is the net worth, insider trading, and ownership report for Stalfort John A Iii. You might contact Stalfort John A Iii via mailing address: C/o Acumen Pharmaceuticals, Inc., 427 Park Street, Charlottesville Va 22902.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
